Bharat Biotech is an Indian Biotechnology company, headquartered in Hyderabad, India. The company was founded by Indian scientist, Krishna Ella. Bharat Biotech has one of the largest pharmaceutical manufacturing plants of its kind in Asia-Pacific.
It is the first bio-pharma facility in the country to be audited and approved by Korean Food & Drugs Administration (KFDA) at Genome Valley, Hyderabad.
Bharat Biotech International Ltd has adopted the policy to produce pure, safe and effective high quality biologicals and biotherapeutics through recombinant DNA and other appropriate technologies towards the creation of a healthier tomorrow. Every effort, scientific and technical, will be made to comply with the requirements for biological and similar products as defined by the National Regulatory Authorities and the World Health Organization. Towards such a realization, Bharat Biotech is committed to implement and execute quality assurance and control policies in accordance with international requirements.
Bharat Biotech International Ltd aims to emerge as a professionally managed, quality-focused biotech company and attain leadership in the manufacture of biologicals and biopharmaceuticals at affordable prices through innovative technologies and eco-safe protocols.
Bharat Biotech: Lead Innovation
|2012||Bharat Biotech & University of Maryland collaboratively received US$ 4 million ‘Strategic Translation Award’ from the Wellcome Trust for clinical development of a new life-saving conjugate vaccine for Invasive Non-Typhoidal Salmonella (iNTS).|
|2010||Bharat Biotech launched HNVAC® – India’s first cell culture-based H1N1 (Human Inactivated Influenza A virus) Swine flu Vaccine.|
|2007||The Company launches BioHib®, India’s first indigenously developed and manufactured Haemophilus Influenza type B (Hib) vaccine.|
|2005||The Company announces a manufacturing and marketing agreement with Cambridge-based Acambis, plc, for developing Japanese Encephalitis vaccine – a neglected disease.|
|2004||Bharat Biotech pioneers India’s First Recombinant Human Epidermal Growth Factors for I & II degree burns, skin grafts, and diabetic foot ulcers – REGEN-D®.|